Clinical Trial Update: Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial updates on erlotinib for locally advanced or metastatic stomach cancer and gastroesophageal junction cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Esophageal Cancer, Gastric Cancer | Phase 2 | Status: COMPLETED